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Thiabendazole (TBZH) reacts with iron(III) nitrate causing protonation of the ligand to yield the nitrate salt [TBZH2NO3] (1).
Reaction of TBZH with copper(II) acetate results in the deprotonation of the ligand yielding [Cu(TBZ)2  (H2O)2] (2). Reactions of
TBZH with the chloride, nitrate and butanedioate salts of copper(II) yields [Cu(TBZH)2Cl]Cl H2O EtOH (3), [Cu(TBZH)2(NO3)2]
(4) and [Cu(TBZH)(O2C–CH2CH2–CO2)] (5), respectively. The TBZH acts as a neutral chelating ligand in 3–5. Molecular struc-
tures of 1 and 3 were determined crystallographically. In 1, the asymmetric unit contains one TBZHþ2 cation and one NO

3 anion.
The structure of 3 comprises a five coordinate copper centre with the metal bound to two chelating TBZH ligands and one chloride.
The geometry is best described as trigonal bipyramidal. Hydrogen bonding connects the complex cation with the uncoordinated
chloride anion and the water and ethanol solvate molecules. Compound 1 and the copper complexes 2–5, the metal free ligands and
a number of simple copper(II) salts were each tested for their ability to inhibit the growth of Candida albicans. The metal free TBZH
and its nitrate salt (1) exhibited very poor activity. Complex 2, in which the TBZH is present as an anionic ligand (TBZ), exhibits
moderate activity towards the pathogen. Chelation of the neutral TBZH to copper centres (complexes 3–5) results in potent anti-
candida activity. The dimethyl sulphoxide (DMSO) soluble complexes 3 and 4, along with metal free TBZH were assessed for their
cancer chemotherapeutic potential towards two human epithelial-derived cancer model cell lines. Complexes 3 and 4 displayed
similar dose-dependent cytotoxicity in both cell lines with IC50 values of approximately 50 lM, which were found to be significantly
lower than that for metal free TBZH.
 2004 Elsevier Inc. All rights reserved.
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Candida albicans is a commensal of the human
body and is considered to be an important fungal
pathogen. Opportunistic infection can lead to the de-
velopment of systemic candidosis which is often fatal in
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Fig. 1. The structure of thiabendazole.
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for systemic fungal infections rely on the use of polyene
and azole anti-fungal drugs, such as nystatin and keto-
conazole. Resistence to these drugs has been reported [5]
and this reduces the efficacy of the therapy and can ul-
timately lead to the death of the patient. Mechanisms
that confer antifungal drug resistence in yeast include an
increase in the expression of drug efflux pumps which
remove the drug from the cell before a toxic concen-
tration can be reached [6], alterations in the target of the
drug and variations in the ergosterol biosynthetic
pathway [7]. The problems associated with the polyene
and azole drugs have resulted in a search for possible
alternative anti-fungal agents [8]. Reports have ap-
peared in the literature describing the anti-fungal ac-
tivity of metal complexes [9]. Due to the possibility of a
difference in mode of anti-fungal activity metal-based
drugs may represent a novel group of anti-mycotic
agents which could have potential applications as
pharmaceuticals.
Recently, we have shown that a range of carboxylate
and dicarboxylate complexes incorporating transition
metal centres and including the N,N0-donor ligand 1,10-
phenanthroline (phen) are potent in vitro inhibitors of
the growth of C. albicans [10–16].
Furthermore, we have shown that by changing the
structural nature of the chelating phenanthroline mole-
cules it is possible to generate complexes that are very
active at much lower concentrations [17]. Experiments
with 1,7-phenanthroline and 4,7-phenanthroline dem-
onstrated that ligands with chelating ability appeared to
be desirable for anti-fungal activity [18]. However, when
the 1,10-phenanthroline is replaced by the structurally
similar N,N0-donor ligand 2,20-bipyridine (bipy) com-
plexes devoid of anti-candida activity are obtained [16].
Significantly, when the 1,10-phenanthroline itself is tes-
ted against the candida it generally exhibits superior
activity to that of the metal complexes and activity
comparable to the prescription drugs. Other workers
have recently reported very good anti-candida activity
for several new organic 1,10-phenanthroline derivatives
[19]. We believe that the so-called ‘‘metal free’’ 1,10-
phenanthroline is probably coordinating to metal ions
that are present in trace amounts in the growth medium
and that it is these resulting metal–phenanthroline
complexes that are responsible for the high anti-candida
activity.
The mode of action of 1,10-phenanthroline and a
number of our potent anti-candida metal complexes
{M¼Cu(II), Mn(II) or Ag(I)} [20] was examined. The
phen and its metal complexes had minimum inhibitory
concentrations (MICs) in the range 1.25–5 lg/ml and at
concentration of 10 lg/ml they displayed some fungi-
cidal activity.
Yeast cells exposed to these drugs showed a dimin-
ished ability to reduce 2,3,5-triphenyltetrazolium chlo-ride (TTC), indicating a reduction in respiratory
function. Treating exponential and stationary phase
yeast cells with phen and the Cu(II) and Mn(II) com-
plexes caused a dramatic increase in oxygen consump-
tion. All of the drugs promoted reduction in levels of
cytochrome b and c in the cells, whilst the Ag(I) com-
plex also lowered the level of cytochrome aa. Cells
treated with phen and the Cu(II) and Ag(I) species
showed reduced levels of ergosterol whilst the Mn(II)
complex induced an increase in the sterol concentra-
tion. The general conclusion was that phen and its
Cu(II), Mn(II) and Ag(I) complexes damage mito-
chondrial function and uncouple respiration. The fact
that these drugs were not uniformly active suggests that
their biological activity has a degree of metal-ion de-
pendency. The effect of these drugs on the structure of
yeast and mammalian cell organelles and the integrity
of cellular DNA was also studied [21]. The conclusion
was that phen and the metal–phen complexes have the
potential to induce apoptosis in fungal and mammalian
cells. 1,10-Phenanthroline and its metal complexes
represent a novel set of highly active anti-fungal agents
whose mode of action is significantly different to that of
the state-of-the-art polyene and azole prescription
drugs. In an effort to extend this class of novel drug, we
have been studying metal complexes containing benz-
imidazole-based ligands. Benzimidazole and many of its
derivatives exhibit a variety of biological actions, in-
cluding antibacterial, antiviral, anticancer and anti-
fungal activity [22].
2-(40-Thiazolyl)benzimidazole{thiabendazole (TBZH)}
(Fig. 1) is a well-known anthelmintic which is non-toxic
to humans [23] and it also has applications as a fungicide
in agriculture [24]. Because of its structural similarity to
the chelating agents 2,20-bipyridine and 1,10-phenan-
throline, we were prompted to try and generate metal
complexes of it. Further interest is derived from TBZH
as it can act as both an acid and a base making it pos-
sible to generate inorganic compounds in which it can be
either neutral, anionic or cationic. Reports of the bio-
logical activity of metal complexes of this potential
N,N0-donor chelating ligand are quite rare. In the pres-
ent paper, we report the synthesis, characterisation and
the fungitoxic activity of inorganic derivatives of TBZH.
To date TBZH is the first N,N0-donor ligand we have
studied that, in vitro, exhibits poor anti-candida activity
on its own but when complexed to a copper(II) centre
becomes a relatively potent drug. In light of the fact that
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metal complexes of TBZH, we also investigated the
chemotherapeutic potential of the free ligand and two of
the novel complexes towards two tumourigenic human
model cell lines.2. Experimental
2.1. Chemistry
Chemicals were purchased from commercial sources
and used without further purification. IR spectra were
recorded in the region 4000–400 cm1 on a Nicolet-400
Impact spectrometer. Magnetic susceptibility measure-
ments were made using a Johnson Matthey Magnetic
Susceptibility balance. [HgCo(SCN)4] was used as a ref-
erence. Satisfactory microanalytical data for the com-
plexes were reported by the Microanalytical Laboratory,
University College Cork, Ireland. [Cu(O2C–CH2CH2–
CO2)]{HO2C–CH2CH2–CO2H¼ butanedioic acid} was
synthesised using a method previously published [12].2.1.1. [TBZH2NO3] (1)
To a solution of Fe(NO3)3  9H2O (0.5 g, 1.24 103
mmol) in ethanol (100 cm3) was added thiabendazole
(TBZH) (0.5 g, 2.47 103 mmol) and the resulting dark
red solution was refluxed for 3 h. Upon standing col-
ourless crystals of the product formed which were fil-
tered and air-dried. Yield: 0.1478 g (45.3%). Calc: C,
45.62; H, 2.68; N, 21.28. Found: C, 45.45; H, 3.02; N,
21.18%. IR (KBr): 3408, 3084, 1635, 1586, 1385, 1347,
1304, 1043, 825, 739, 535 cm1. Solubility: soluble in
ethanol and methanol.2.1.2. [Cu(TBZH)2  (H2O)2] (2)
To a solution of thiabendazole (TBZH) (2.01 g, 10.00
mmol) in ethanol (100 cm3) was added [Cu2(CH3CO2)2 
2H2O] (1.00 g, 5.00 mmol) and the resulting dark green
solution was refluxed for 4 h. The dark green solid which
deposited was filtered off, washedwith water and ethanol,
and then air-dried.Yield: 2.40 g (96%). Calc: C, 48.03; H,
3.22; N, 16.81. Found: C, 48.99; H, 2.60; N, 16.74%. IR
(KBr): 3427, 3082, 1605, 1474, 1409, 1359, 1294, 1269,
1228, 1015, 933, 908, 875, 834, 744 cm1. leff : 1.64 B.M.
Solubility: insoluble in water, ethanol, methanol, acetone
and trichloromethane.2.1.3. [Cu(TBZH)2Cl]Cl H2O EtOH (3)
To a solution of thiabendazole (TBZH) (3.14 g, 7.40
mmol) in ethanol (100 cm3) was added CuCl2  2H2O (1
g, 7.40 mmol) and the resulting light green solution was
refluxed for 4 h. The light green solid which deposited
was filtered off, washed with water and ethanol, andthen air-dried. Yield: 2.70 g (64%). Calc: C, 43.12; H,
3.17; N, 13.98. Found: C, 43.12; H, 3.28; N, 13.91%. IR
(KBr): 3443, 3328, 3221, 3074, 2967, 2828, 2764, 1630,
1597, 1513, 1491, 1466, 1441, 1326, 1294, 1228, 1189,
1080, 1048, 1015, 998, 933, 875, 842, 744, 670 cm1. leff :
1.57 B.M. Solubility: insoluble in water, ethanol, meth-
anol, acetone and trichloromethane.2.1.4. [Cu(TBZH)2(NO3)2] (4)
To a solution of thiabendazole (TBZH) (1.80 g, 9.02
mmol) in ethanol (100 cm3) was added
Cu(NO3)2  2H2O (1.00 g, 4.29 mmol) and the resulting
lime green solution was refluxed for 4 h. The lime green
solid which deposited was filtered off, washed with
water and ethanol, and then air-dried. Yield: 2.57 g
(98%). Calc: C, 40.68; H, 2.37; N, 18.48. Found: C,
40.54; H, 2.39; N, 18.51%. IR (KBr): 3098, 2360, 1593,
1517, 1441, 1409, 1384, 1329, 1289, 1228, 1015, 998,
933, 875, 842, 769, 744 cm1. leff : 1.71 B.M. Solubility:
insoluble in water, ethanol, methanol, acetone and
trichloromethane.2.1.5. [Cu(TBZH)(bda)] (5)
To a solution of thiabendazole (TBZH) (0.60 g, 3.00
mmol) in ethanol (50 cm3) was added [Cu(O2C–
CH2CH2–CO2)] (0.50 g, 1.53 mmol) and the blue sus-
pension was refluxed for 4 h. The resulting blue solid
which deposited was filtered off, washed with water and
ethanol, and then air-dried. Yield: 0.62 g (69%). Calc: C,
44.15; H, 2.91; N, 11.03. Found: C, 44.38; H, 2.85; N,
11.67%. IR (KBr): 3427, 3115, 2918, 2352, 1557,
1425,1409, 1285, 1228, 1187, 1015, 974, 941, 875, 834,
777, 637 cm1. leff : 1.74 B.M. Solubility: insoluble in
water, ethanol, methanol, acetone and trichloromethane.2.2. X-ray crystallography
The two data sets were collected at 150(2) K on a
Bruker SMART 1000 diffractometer using Mo Ka ra-
diation (k ¼ 0:71073 A). Each was solved by direct
methods and refined by full-matrix least-squares on F2.
All the non-hydrogen atoms were refined with aniso-
tropic atomic displacement parameters and hydrogen
atoms bonded to carbon were inserted at calculated
positions using a riding model. In 1, the hydrogen atoms
bonded to nitrogen were located in the difference map
but then inserted at calculated positions using a riding
model. In 3, the hydrogen atoms bonded to nitrogen
were located from difference maps and not further re-
fined; that bonded to the ethanol oxygen atom in 3 was
treated in the same way. Hydrogen atoms bonded to
water molecules were not included in the models. Details
of the collection and refinement are given in Table 1 . All
programmes used in the structure solution and refine-
ment are contained in the SHELXTL package [25].
Table 1
Crystal data and structure refinement for 1 and 3
Compound [TBZH2NO3] (1) [Cu(TBZ)2Cl]Cl H2O EtOH (3)
Empirical formula C10H8N4O3S C22H22Cl2CuN6O2S2
Formula weight 264.26 601.02
Crystal system Monoclinic Monoclinic
Space group P21=n P2=c
a (A) 4.8074(7) 16.2813(8)
b (A) 13.812(2) 11.3482(6)
c (A) 16.619(3) 15.6061(8)
b () 97.779(2) 118.075(1)
Volume (A3) 1093.4(3) 2544.1(2)
Z 4 4
Density (calc) (Mg/m3) 1.605 1.569
Absorption coefficient (mm1) 0.303 1.266
F ð000Þ 544 1228
Crystal size (mm3) 0.42 0.17 0.09 0.20 0.15 0.15
Crystal description Yellow block Green needle
h range () 1.92–25.00 1.42–28.92
Index ranges 56 h6 5, 166 k6 15, 196 l6 19 216 h6 22, 156 k6 14, 206 l6 20
Reflections collected 7359 29,636
Independent reflections [Rint] 1926 [0.0275] 6164 [0.0484]
Tmax; Tmin 1.00000, 0.771000 0.928078, 0.762571
Data/restraints/parameters 1926/0/163 6164/0/316
Goodness-of-fit on F 2 1.060 1.013
Final R indices ½I > 2rðIÞ R1 ¼ 0:0376, wR2 ¼ 0:0987 R1 ¼ 0:0484, wR2 ¼ 0:1321
R indices (all data) R1 ¼ 0:0434, wR2 ¼ 0:1035 R1 ¼ 0:0820, wR2 ¼ 0:1534
Largest difference peak and hole (eA3) 0.481 and )0.537 0.820 and )0.561
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Candida albicans isolate was obtained commercially
from Oxid Culti-loops (ATCC 10241). The isolate was
stored on Sabouraud dextrose agar (SDA) plates at
4 C. Culture conditions and measurement of drug
minimum inhibitory concentrations (MICs) were as
previously described [11].
2.4. Cytotoxicity testing
Dimethyl sulphoxide (DMSO) and all cell culture
reagents and media were purchased from Signa–Aldrich
Ireland, Ltd, unless otherwise stated.
2.5. Cell lines and cell culture
Cytotoxicity assays were performed using two human
model cell lines in order to assess the cancer chemo-
therapeutic potential of metal free TBZH and complexes
3 and 4 (the other complexes were not soluble in
DMSO). The human malignant melanoma (melanocyte)
skin cell line (SK-MEL-31) and squamous carcinoma
tongue cell line (CAL-27) were purchased from the
American Type Culture Collection, Manassas. SK-
MEL-31 cells were grown as a monolayer in Eagles
minimum essential medium, supplemented with 2 mM
L-glutamine and Earles balanced salt solution, con-
taining 1.5 g/L sodium bicarbonate, 0.1 mM non-es-sential amino acids, 1.0 mM sodium pyruvate, 100 U/ml
penicillin and 100 lg/ml streptomycin supplemented to
contain 15% (v/v) foetal bovine serum (Flow laborato-
ries, Herts, UK). The CAL-27 cells were grown in
Dulbeccos modified Eagles medium, supplemented
with 4 mM L-glutamine, containing 1.5 g/L sodium bi-
carbonate, 0.1 mM non-essential amino acids, 1.0 mM
sodium pyruvate, 100 U/ml penicillin and 100 lg/ml
streptomycin supplemented to contain 15% (v/v) foetal
bovine serum. Both model cells were grown at 37 C in a
humidified atmosphere, in the presence of 5% CO2 and
were in the exponential phase of growth at the time of
assay.
2.6. Assessment of cytotoxicity, using MTT assay
Test compounds were dissolved in DMSO, diluted in
culture media and used to treat the two model cells over
a drug concentration range 0.1–1000 lM for a period of
96 h. SK-MEL-31 and CAL-27 cells were seed at a
density of 3.5 104 and 5 103 cells/well, respectively,
into sterile 96 well flat-bottomed plates (Falcon Plastics,
Decton Dickinson) and grown in 5% CO2 at 37 C. A
miniaturised viability assay using 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was
carried out according to the method described by
Mosman [26]. The IC50 value was calculated for each
drug and used as a means for comparing the toxicity of
each of the derivatives tested. Consequently, IC50 was
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duction in cellular viability. Each assay was carried out
using five replicates and repeated on at least three sep-
arate occasions. Viability was calculated as a percentage
of solvent treated control cells, and expressed as per-
centage of control. The significance of any reduction in
cellular viability was determined using one-way ANO-
VA (analysis of variance). A probability of 0.05 or less
was deemed statistically significant.3. Results and discussion
3.1. Synthesis and characterisation of the compounds
Five inorganic derivatives of TBZH in which the li-
gand is protonated {[TBZH2NO3] (1)}, deprotonated
{[Cu(TBZ)2  (H2O)2] (2)} and neutral {[Cu(TBZH)2-
Cl]Cl H2O EtOH (3), [Cu(TBZH)2(NO3)2] (4) and
[Cu(TBZH)(bda)] (5)} were generated in moderate to
good yield using the reactions shown in Scheme 1. The
non-metal-based nitrate salt [TBZH2NO3] (1) was the
major product of a reaction between TBZH and
Fe(III)(NO3)3. Attempts to generate this salt using a
direct method involving nitric acid and TBZH have so
far been unsuccessful and the mechanism of the for-
mation of the salt is unknown. Hydrated Fe(III) salts
are known to act as aqua acids, a fact which could ex-
plain the protonation of the TBZH molecule during this
reaction. Failure to isolate any iron complex formed
during the reaction may well be due to the fact that
Fe(III) compounds are not particularly stable.
The formulation of the compounds was assigned on
the basis of their elemental analysis, IR spectra and X-
ray analysis (for 1 and 3). In the respective IR spectra
the majority of the ligand absorption bands, some of
them with changed intensity, appear again in the
compounds. In 1, the N–H stretching band at 3093
cm1 has shifted to 3084 cm1 and has become more
intense. Furthermore, the band associated to the imi-
dazolic m(C@N) at 1577 cm1 in the free ligand has
completely disappeared in the cationic TBZHþ2 due to
protonation on the benzimidazole imine nitrogen, re-TBZH
[Cu(TBZH)(Bda)]  (5)
{Cu(Bda)(H2O)}n
[TBZH2NO3]  (1)
Fe(NO3)2 Cu(NO3)2.2H2O
[Cu(TBZH)2(NO3)2]  (4)
CuCl2.2H2O
[Cu(TBZH)2CL]Cl.H2O.EtOH  (3)
[Cu2(CH3COO)4.2H2O]
[Cu(TBZ)2(H2O)2]  (2)
Scheme 1.sulting in delocalisation of the double bond over the N–
C–N section. A strong absorption band at approxi-
mately 1385 cm1 in the spectrum of 1 (which does not
appear for the ligand) is characteristic of a nitrate
group [27].
The anionic nature of the ligand in 2 is evident when its
spectrum is compared to that of TBZH. The prominent
bands at 3093 cm1 (N–H stretching) and at 1093 cm1
(N–H vibration) for the free ligand were absent in the
spectrum of 2. Also for 2, the band associated to the im-
idazolic m(C@N) at 1577 cm1 in the free ligand has
shifted to 1605 cm1 due to deprotonation of the imi-
dazolic nitrogen. In the spectra of complexes 3 and 4 the
m(C@N)imidazolic and m(C@N)thiazolic bands (1577 and 1480
cm1, respectively) are shifted (to 1597 and 1513 cm1 for
3; 1593 and 1517 cm1 for 4) indicating that the ligand is
coordinated through the imidazolic and the thiazolic ni-
trogens. The asymmetrical carboxylate stretching band
precludes a similar assignment in the spectrum of 5. For
all four complexes 2–5 the C–S stretching band (at 1228
cm1 for the free ligand) remains essentially unchanged
suggesting that the sulphur atom in the thiazole ring is
uncoordinated. New bands in the spectrum of 4 at ap-
proximately 1441 and 1289 cm1 are assigned to an un-
coordinated nitrate group whereas a new band at 1329
cm1 is indicative of the presence of a coordinated nitrate.
As well as the bands that have been assigned to chelating
TBZH ligands the spectrum of 5 has bands that are
characteristic of carboxylate anions {m(OCO)assym at 1557
cm1 and m(OCO)sym at 1409}. The calculated D(OCO)
value {m(OCO)assym ) m(OCO)sym} of 148 cm1 is typical
for a carboxylate group bound to a metal in a chelating
coordination mode [28]. Whereas the room temperature
magnetic susceptibility values for 4 and 5 are close to
those expected for simple copper(II) species (i.e., those
lacking Cu–Cu interactions) the values for 2 and 3 are
slightly lower and some form of antiferromagnetic inter-
action may be taking place in these complexes [29]. With
the exception of the nitrate salt all of the complexes are
effectively insoluble in common solvents. Complexes 3
and 4 were found to be soluble in DMSO.
Crystals suitable for X-ray analysis were isolated for
compounds 1 and 3. The structure of [TBZH2NO3] (1) is
shown in Figs. 2 and 3, and bond lengths and angles areFig. 2. The asymmetric unit of [TBZH2NO3] (1).
Table 2
Bond lengths (A) and angles () for [TBZH2NO3] (1)
C(1)–C(3) 1.364(3)
C(1)–S(1) 1.698(2)
S(1)–C(2) 1.7209(19)
C(2)–N(1) 1.303(3)
N(1)–C(3) 1.379(2)
C(3)–C(4) 1.441(3)
C(4)–N(2) 1.338(2)
C(4)–N(3) 1.341(2)
N(2)–C(5) 1.385(3)
C(5)–C(6) 1.390(3)
C(5)–C(10) 1.398(3)
C(6)–C(7) 1.379(3)
C(7)–C(8) 1.407(3)
C(8)–C(9) 1.378(3)
C(9)–C(10) 1.389(3)
C(10)–N(3) 1.381(3)
N(11)–O(13) 1.235(2)
N(11)–O(11) 1.254(2)
N(11)–O(12) 1.258(2)
C(3)–C(1)–S(1) 110.24(15)
C(1)–S(1)–C(2) 89.13(10)
N(1)–C(2)–S(1) 115.73(15)
C(2)–N(1)–C(3) 109.33(16)
C(1)–C(3)–N(1) 115.57(18)
C(1)–C(3)–C(4) 124.90(18)
N(1)–C(3)–C(4) 119.53(16)
N(2)–C(4)–N(3) 109.24(17)
N(2)–C(4)–C(3) 125.10(17)
N(3)–C(4)–C(3) 125.66(17)
C(4)–N(2)–C(5) 108.96(15)
N(2)–C(5)–C(6) 131.75(17)
N(2)–C(5)–C(10) 106.31(17)
C(6)–C(5)–C(10) 121.94(18)
C(7)–C(6)–C(5) 116.20(18)
C(6)–C(7)–C(8) 121.90(19)
C(9)–C(8)–C(7) 121.87(19)
C(8)–C(9)–C(10) 116.41(18)
N(3)–C(10)–C(9) 131.64(17)
N(3)–C(10)–C(5) 106.68(16)
C(9)–C(10)–C(5) 121.68(18)
C(4)–N(3)–C(10) 108.80(16)
O(13)–N(11)–O(11) 120.53(17)
O(13)–N(11)–O(12) 119.37(16)
O(11)–N(11)–O(12) 120.09(16)
Table 3
Hydrogen bonds for [TBZH2NO3] (1) (A and )
D–HA d(D–H) d(H  A) d(DA) \(DHA)
N(2)–H(2A)O(12)#1 0.88 1.91 2.785(2) 175.3
N(2)–H(2A)O(13)#1 0.88 2.58 3.213(2) 129.7
N(3)–H(3)O(11)#2 0.88 1.98 2.856(2) 170.9
Symmetry transformations used to generate equivalent atoms: #1
Fig. 3. A view of the p–p stacking in [TBZH2NO3] (1).
1028 M. Devereux et al. / Journal of Inorganic Biochemistry 98 (2004) 1023–1031listed in Table 2. The asymmetric unit contains one
protonated TBZH2 cation and one nitrate anion. The
TBZH is protonated on the benzimidazole imine nitro-
gen, resulting in delocalisation of the double bond over
the N–C–N section (Table 2). The cations are hydrogen
bonded (Table 3) to nitrate anions via each of the NH
groups, resulting in a chain along which adjacent
TBZH2 units are oriented at approximately right angles
to each other. There is significant pp-stacking between
adjacent TBZH2 cations with an interplanar distance ca.
3.3 A.
The structure for [Cu(TBZH)2Cl]Cl H2O EtOH (3)
is shown in Figs. 4–6 and selected bond lengths and
angles are listed in Table 4. The copper ion is five-co-
ordinate, bound to two TBZH ligands via a-diimine
units and to one chloride anion (Fig. 4). The geometry at
copper is irregular but perhaps best described as trigonal
bipyramidal with the benzimidazole nitrogen atoms N2
and N12 as apical donors (N2–Cu–N12 171.9(1)). The
benzimidazole NH groups N1 and N11 are hydrogen
bonded to Cl1 of a neighbouring cation and to Cl2,
respectively (Table 5 and Fig. 5). The OH protons of the
solvate water and ethanol molecules are also involved
on hydrogen bonding (Fig. 4), resulting in a 3D network
of hydrogen bonding extending through the lattice and
supported by p–p-interactions (Fig. 6).
xþ 1=2; y þ 1=2;zþ 3=2 and #2 x;y þ 1;zþ 1.3.2. Biological activities
The nitrate salt of TBZH (1), all of the copper com-
plexes {2–5 and [Cu(O2C–CH2CH2–CO2)]}, the free li-
gands and a selection of simple copper salts were each
tested for their ability to inhibit the growth of C. albicans(Table 6). Butanedioic acid (HO2C–CH2CH2– CO2H)
and the simple copper salts are essentially inactive against
the pathogen. Furthermore, coordination of butanedioic
acid to a copper center {[Cu(O2C–CH2CH2–CO2)]} does
not result in any significant improvement in the activity
Table 4
Selected bond lengths (A) and angles () for [Cu(TBZ)2Cl]Cl H2O 
EtOH (3)
Cu–N(2) 1.972(3)
Cu–N(12) 1.975(3)
Cu–N(3) 2.076(3)
Cu–N(13) 2.153(3)
Cu–Cl(1) 2.3050(11)
N(2)–Cu–N(12) 171.91(13)
N(2)–Cu–N(3) 80.75(12)
N(12)–Cu–N(3) 95.98(12)
N(2)–Cu–N(13) 95.27(11)
N(12)–Cu–N(13) 79.98(11)
N(3)–Cu–N(13) 120.82(12)
N(2)–Cu–Cl(1) 95.22(9)
N(12)–Cu–Cl(1) 92.34(10)
N(3)–Cu–Cl(1) 134.35(9)
N(13)–Cu–Cl(1) 104.82(9)
Table 5
Hydrogen bonds for [Cu(TBZ)2Cl]Cl H2O EtOH (3) (A and )
D–H  A d(D–H) d(HA) d(DA) \(DHA)
N(1)–H(1)Cl(1)#1 0.91 2.37 3.209(3) 152.2
N(11)–H(11)Cl(2)#2 0.88 2.18 3.050(3) 168.3
O(21)–H(21)O(1W) 0.88 1.89 2.732(7) 161.4
N(1)–H(1)Cl(1)#5 0.91 2.77 3.398(3) 126.6
O1WCl2#3 3.187(5)
O1WCl2#4 3.158(4)
Symmetry transformations used to generate equivalent atoms: #1
x;y þ 1; zþ 1=2, #2 x;y;z, #3 x;y; zþ 1=2, #4 x; y;zþ 1=2
and #5 xþ 1;y þ 1;zþ 1.
Fig. 6. The packing diagram in [Cu(TBZH)2Cl]Cl H2O EtOH (3).
Fig. 5. Hydrogen bonding in [Cu(TBZH)2Cl]Cl H2O EtOH (3).
Fig. 4. The structure of the cation in [Cu(TBZH)2Cl]Cl H2O EtOH
(3).
Table 6
Anti-candida activitya
Test compound % Cell growth
Control 100
Ketoconazole 20
1,10-Phenanthroline 15
CuCl2 95
CuNO3 98
Cu(OAc)2 94
HO2C–CH2CH2–CO2H 98
[Cu(O2C–CH2CH2–CO2)] 95
TBZH 76
[TBZH2NO3] (1) 60
[Cu(TBZ)2(H2O)2] (2) 54
[Cu(TBZH)2Cl]Cl H2O EtOH (3) 29
[Cu(NO3)2(TBZH)2] (4) 30
[Cu(TBZH)(O2C–CH2CH2–CO2)] (5) 19
a The compounds were tested at concentrations of 10 lg/ml of
aqueous RPMI medium. Complexes 2–5 were insoluble in water and
were used as suspensions. Yeast cells were grown for 24 h at 37 C.
Results are presented as % cell growth and the effectiveness of the
compounds are compared to the growth of the control (no drug
added).
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very poor inhibitor of the growth of the pathogen.
Compound 1 and complex 2 (in which the ligand is foundin its cationic and anionic states, respectively) are
both moderate anti-candida agents. Significantly when
the neutral TBZH is coordinated to a copper center
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Fig. 8. Effects of TBZH, 3 and 4 on the viability of SK-MEL-31 cells
following continuous incubation with increasing drug concentration
(0.1–1000 lM) for 96 h. Bars indicate standard error of the mean
(SEM) and results were statistically significant from control at
p < 0:05.
Table 7
The chemotherapeutic potential of TBZH 3 and 4
Test compound Toxicities (IC50, lM)
CAL-27
(means SD)
SK-MEL-31
(means SD)
TBZH 676.7 12.0 453.3 66.0
[Cu(TBZH)2Cl]Cl H2O EtOH (3) 55.0 0.0 49.5 7.7
[Cu(NO3)2(TBZH)2] (4) 54.0 2.5 46.7 5.0
Cancer chemotherapeutic potential of complexes 3 and 4 along
with metal free TBZH in CAL-27 and SK-MEL-31, following con-
tinuous incubation for 96 h in the concentration range 0.1–1000 lM,
using MTT assay. A graph of viability as % of solvent treated control
verses drug concentration was used to calculate IC50 values (lM),
(meansSD; n ¼ 5).
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duced. Complex 5 exhibits the greatest fungitoxic activity
and indeed is comparable to the prescription drug keto-
conazole at this concentration. Preliminary studies on the
mode of action of the copper TBZH complexes have re-
vealed that they cause a reduction in the ergosterol con-
tent of the fungal cells [30] which was also found to be the
case for the phenanthroline complexes previously re-
ported [20].
The chemotherapeutic potential of TBZH and the
DMSO soluble complexes 3 and 4 was determined by
calculation of IC50. Calculation of this value allows a
direct comparison of the cytotoxicity of each of the
test agents. The IC50 values were calculated using the
data presented in Figs. 7 and 8. The values were
obtained for each compound and in each cell line
(Table 7). TBZH was capable of killing both cancer-
derived cell lines only at higher concentrations with
IC50 value of 453 and 677 lM (equivalent to 91.7 and
136.9 lg/ml), for the tongue and skin cell line, re-
spectively. In the case of compounds 3 and 4, the IC50
values were very similar across the two human model
cell lines. They had almost identical IC50 values of 55
and 54 lM (equivalent to 33.1 and 31.9 lg/ml), re-
spectively, in the CAL-27 cell line and 50 and 47 lM
(equivalent to 39.1 and 30.7 lg/ml), respectively in the
SK-MEL-31 cell line. Although the activities of 3 and
4 do not fall within the accepted activity parameters
adopted for in vitro screening (i.e., IC50 values not
exceeding 4 lg/ml) [31] the results suggest the che-
motherapeutic potential of TBZH is significantly en-
hanced upon coordination to a metal centre.
Furthermore, the cytotoxic activity of all three com-
pounds is concentration dependent for both cell lines
(Figs. 7 and 8).Conc. (µM)
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Fig. 7. Effects of TBZH, 3 and 4 on the viability of CAL-27 cells
following continuous incubation with increasing drug concentration
(0.1–1000 lM) for 96 h. Bars indicate standard error of the mean
(SEM) and results were statistically significant from control at
p < 0:05.4. Conclusion
Neutral thiabendazole (TBZH) when uncoordinated
to a metal centre is a poor anti-Candida agent and has
very little chemotherapeutic potential. Protonation of
TBZH to form the nitrate salt 1 and its deprotonation to
yield the complex 2 results in only moderate improve-
ment in its anti-candida activity. Complexes 3–5, in
which the TBZH is present as a neutral chelating ligand,
are all potent anti-candida agents with five possessing
activity comparable to the prescription drug ketocona-
zole. Coordination of neutral TBZH to a copper centre
in complexes 3 and 4 resulted in a significant increase in
its chemotherapeutic potential.5. Supplementary data
Crystallographic data have been deposited with the
CCDC (12 Union Road, Cambridge, CB2 1EZ, UK)
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numbers 219675 and 219676, respectively.Acknowledgements
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